CClinicalTrials.gg
Status unknownNCT04496011Updated Aug 3, 2020

Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation

An interventional study of Aerobic training with cycle ergometer in Fatigue, Leukemia and Lymphoma, sponsored by Federal University of Health Science of Porto Alegre. Status unknown at 1 site in Brazil. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-08-03.

Sponsored by Federal University of Health Science of Porto Alegre · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2020), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2020, registered Jun 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Physiological changes caused by hematological diseases associated with high dose chemotherapy have a negative impact on patient's functionality, making them more fragile and vulnerable after hematopoietic cell transplantation. Currently, randomized studies have shown that physical exercise can contribute to improve Quality of Life of these patients. In this randomized controlled trial, we will study the effect of using the bicycle ergometer on the physical performance of patients undergoing transplantation of hematopoietic stem cells (HSCT).

Read the detailed description

The sample consists of 30 patients diagnosed with leukemia, lymphoma and multiple myeloma, undergoing high-dose chemotherapy and hematopoietic stem cells transplantation, who will be randomized into two groups. The results of muscle strength in the lower limbs, general mobility, fatigue and clinical symptoms will be compared between the control group and the experimental group.

The control group will perform an exercise program based on the standard protocol of the physiotherapy service, where exercises are performed to gain strength in muscle groups of the upper and lower limbs, range of motion, balance and functional movements. The experimental group will perform the same exercises as the control group, added to a training program using a bicycle ergometer, with an incremental load (from 60% to 70% of the maximum heart rate) for 20 minutes.

02

Conditions studied

  • Fatigue
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Hematopoietic Stem Cell Transplantation

Keywords

  • Autologous transplant
  • Allogeneic transplant
  • Physiotherapy
  • Exercise
  • Fatigue
03

In context

Multiple Myeloma

3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.

This study's planned enrollment of 30 is below the median of 41 across 2,907 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Federal University of Health Science of Porto Alegre is the lead sponsor of 118 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patients (18-70 years) scheduled to perform the first HSCT;
  • Be with a preserved neurological function and full cognition;
  • Have clinical conditions that allow participation in the motor physiotherapy program;
  • Be agreed with a study proposal and sign the free and informed consent form (ICF).

Exclusion criteria

Exclusion Criteria:

  • Develop clinical complications that contraindicate the performance of motor physiotherapy including the practice of the cycle ergometer;
  • Present a previous musculoskeletal alteration that interferes with the performance of physical performance assessment tests;
  • Recent cardiovascular or pulmonary disease;
  • Psychiatric or neurological disorder;
  • Need for gait assistance or presence of bone metastasis
  • Adherence below 50% of the total motor physiotherapy protocol.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    In this group the exercise program will be based on the protocol of Control Group, without the exception of walking training, adding aerobic capacity training using the bicycle ergometer, model CBL11 Classic® from ACT®.

    Other: Aerobic training with cycle ergometer

  • No intervention
    Group Control

    In this group the exercise program is based on the standard physiotherapy protocol that is part of the care routines performed at the bone marrow transplant service. It includes essential components of a rehabilitation program: range of motion, balance training, gait and strength of the upper and lower limbs

Interventions

  • OtherAerobic training with cycle ergometer

    Patients start with an initial warm-up of 2 minutes, with rotations per minute free, without load. Progressively, the load of the exercise cycle increases every minute up to the supported limit or up to 60% - 70% of maximum heart rate (HRmax). The training will be carried out for 20 continuous minutes, being interrupted whenever the heart rate (HR) reaches 90% of the maximum expected for the age and / or the loss of effort perceived in the BORG scale, above 8 on a scale of 0 to 10.

06

What researchers measure

Primary outcomes

  1. Lower Limb Physical Functioning and Strength

    The 30-Second Chair Stand evaluates lower limb strength and, indirectly, the risk of falls, especially in the elderly population (JONES, J., RIKLI, 2002). This way, it will compose the set of tests used to determine the physical performance by measuring the number of stands from an armless chair of standard height (45 cm) performed in 30 seconds. The test will be begin when the participant, seating on a neutral spine position and feet flat on the floor, will be instructed to rise to a full stand and return to the original seated position, as quickly as possible. The participant will be instructed to move at maximal speed until they either feel the need to stop or the 30-second time limit is reached. More than 8 unassisted stands for men and women are considered above average for their age, and those below the range as below average

    Time frame: Trough study completion, an average of 2 months

Secondary outcomes

  1. Fatigue

    Piper Fatigue Scale, developed by Piper et al. (1998), is a multidimensional measure of fatigue in the field of cancer research and includes subdomains of the behavioral, affective, sensorial and cognitive attributes / fatigue mood, composed of 22 items. The scores for each item range from 0 to 10 and can total 220 points. Higher values characterize a greater perception of fatigue. It will be applied on patient's evaluation day and on hospital discharge day.

    Time frame: Trough study completion, an average of 2 months

  2. Symptoms Assessment

    The Edmonton Symptom Assessment Scalemorning will be applied to eavaluate symptoms of pain, tiredness, drowsiness, appetite, nausea, shortness of breath, depression, anxiety and well-being. It is a scale where the patient provides an auto-report on a score that can vary from 0 to 10, being score 0 absence of symptoms and 10 represents the most intense sensation experienced by the patient.

    Time frame: Trough study completion, an average of 2 months

  3. Timed up and Go (TUG)

    TUG is used in clinical practice to assess mobility, the risk of falls and also to assist in the diagnosis of sarcopenia. For this reason, that test will be compiled or set of tests that will be used to determine physical performance.

    Time frame: Trough study completion, an average of 2 months

07

Study locations

1 of 1 sites recruiting
  • Universidade Federal de Ciências da Saúde de Porto Alegre - UFCSPA
    Porto Alegre, RS 90050-170, Brazil
    • Fabricio Edler Macagnan, PhD · Contact · fabriciom@ufcspa.edu.br · +55 (51) 3309.8876
    • Michele Adriane Froelich, Superior · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04496011
Lead sponsor
Federal University of Health Science of Porto Alegre
Responsible party
Fabrício Edler Macagnan (Sponsor-Investigator, Federal University of Health Science of Porto Alegre) — Principal investigator
First posted
Aug 3, 2020
Start date
Mar 2, 2020
Primary completion
Sep 30, 2020 (estimated)
Completion
Dec 2020 (estimated)
Last update
Aug 3, 2020

Study contacts

Fabricio Edler Macagnan, PhD
Contact
fabriciom@ufcspa.edu.br
+55 (51) 3309.8876
Fabricio Edler Macagnan, PhD
principal investigator · Federal University of Health Science of Porto Alegre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion